This case raises multiple lingering questions regarding the management of patients with mucinous ovarian carcinoma, including the role of HER2-targeted therapy in the treatment of advanced stage disease, the ideal management and prognostication of patients with stage IC disease, and the genetic and environmental risk factors specific to mucinous ovarian tumors. Here, ERBB2 is linked to ovarian mucinous adenocarcinoma.